marijuana stocks news

Form 8-K for CANNAVEST CORP.


18-May-2015

Results of Operations and Financial Condition, Regulation FD Disclosure

Item 2.02 Results of Operations and Financial ConditionThe information provided below in “Item 7.01- Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

 

Item 7.01 Regulation FD DisclosureOn May 15, 2015, CannaVEST Corp. (the “Company”) announced the release of its First Quarter 2015 earnings. A copy of the press release issued by the Company announcing the release of First Quarter 2015 earnings is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tetra Bio-Pharma Inc. (TBPMF) Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.…

$TRTC Edible Garden, Awarded New Food Compliant Certifications

Terra Tech Subsidiary, Edible Garden, Awarded New Food Compliant Certifications Certifications include…

Verano Holdings Corp. (VRNOF) Announces the Opening of MÜV Orlando Colonial

Verano Announces the Opening of MÜV Orlando Colonial, the Company’s 64th Florida…

GT Biopharma Inc. (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2 Trial

GT Biopharma (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2…